◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Insmed Inc (INSM) Net Income 2006–TTM

Name: Insmed Inc (INSM) net income history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Insmed Inc annual net income for fiscal TTM was -$875 million, an increase of 31.5% from -$1.3 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

INSM Annual Net Income

Net Income (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Net Income	($875M)	($1.3B)	($914M)	($750M)	($482M)	($435M)	($294M)	($254M)	($324M)	($193M)	($176M)	($118M)	($79M)	($56M)	($41M)	($60M)	($6M)	$118M	($16M)	($20M)	($56M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INSM Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Net Income	($13M)	($164M)	($328M)	($370M)	($322M)	($257M)	($236M)	($221M)	($301M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

RPRX Net Income — Royalty Pharma Plc
ALNY Net Income — Alnylam Pharmaceuticals Inc
ROIV Net Income — Roivant Sciences Ltd
JAZZ Net Income — Jazz Pharmaceuticals PLC
ASND Net Income — Ascendis Pharma AS

More INSM metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All INSM financial statements → Interactive INSM charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.